Skip to main content
NAVCO Pharmaceuticals logo

NAVCO Pharmaceuticals — Investor Relations & Filings

Ticker · NAV ISIN · CA63942R1091 LEI · 8945003WKDH61M8UB963 TSXV Manufacturing
Open in API
Filings indexed 199 across all filing types
Latest filing 2022-10-26 Regulatory Filings
Country CA Canada
Listing TSXV NAV

About NAVCO Pharmaceuticals

https://www.navcopharma.com/

NAVCO Pharmaceuticals is a biotechnology company specializing in the research, development, and commercialization of nanotechnology products and materials. The company utilizes proprietary Computerized Nano-meter Algorithms to create innovative solutions for anti-viral, anti-fungal, and anti-bacterial treatments. NAVCO focuses on developing supplemental and therapeutic consumer health and wellness products. A key offering is the BioActive™ line, which includes non-toxic, non-flammable, and alcohol-free hand cleansers, creams, and surface disinfectants designed to provide extended protection against germs and microorganisms. These nanotechnology products are marketed across various sectors, including medicine and textiles, providing next-generation protection solutions for multiple industries.

Recent filings

Filing Released Lang Actions
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 13-501F1 related to reporting issuers and participation fees, including a management certification by an officer (CEO) certifying the accuracy of the information submitted to the Alberta Securities Commission. It contains detailed financial data such as market values, capitalization, participation fees, and trading periods. The presence of a management certification and detailed financial figures indicates this is a regulatory filing form rather than a full annual or interim report. The document is not an announcement or a brief summary but a formal certification and submission form. Therefore, it fits best under Regulatory Filings (RNS), which covers officer certifications and miscellaneous regulatory documents that do not fit other categories.
2022-10-26 English
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 98% confidence The document is titled 'INDEPENDENT AUDITOR'S REPORT' and contains detailed audit opinion language, including the auditor's responsibilities, basis for opinion, and a material uncertainty related to going concern. It includes audited financial statements such as the statements of financial position, operations and comprehensive loss, changes in shareholders' equity, cash flows, and notes to the financial statements for the year ended June 30, 2022. The presence of an auditor's report with detailed financial statements and notes indicates this is a standalone audit report rather than a full annual report or other filing. The document length is substantial (15,000 characters), and it contains actual financial data and audit opinion, not just an announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2022
2022-10-26 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2022-05-30 English
Interim MD&A - English.pdf
Regulatory Filings
2022-05-30 English
Interim financial statements/report – English.pdf
Regulatory Filings
2022-05-30 English
Interim financial statements/report – English.pdf
Regulatory Filings
2022-03-01 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.